{
    "clinical_study": {
        "@rank": "38619", 
        "acronym": "SAIF", 
        "arm_group": {
            "arm_group_label": "SImmetry Implant", 
            "description": "Subjects who are indicated for the SImmetry Device according to the approved product labeling and inclusion/exclusion criteria will receive a SImmetry implant."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the SAIF study is to evaluate the SImmetry Sacroiliac Joint Fusion System for\n      fusion and pain reduction of the SI joint."
        }, 
        "brief_title": "SAIF: Sacroiliac Fusion Study", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Sacroiliac Joint Dysfunction", 
        "condition_browse": {
            "mesh_term": "Joint Diseases"
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, non-randomized, single center study to collect data on fusion and\n      pain reduction following implantation of the SImmetry device. Up to 15 total subjects will\n      be implanted and followed for 24 months. Data will be collected pre-operatively, at implant,\n      discharge, and at specified follow-up time points (6 weeks, 3 months, 6 months, 12 months,\n      24 months.)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must be indicated for the SImmetry device according to the approved SImmetry\n             labeling\n\n          -  Subject has three (3) positive (experiences pain) Provocative Tests for SIJ pain; for\n             example, Compression, Thigh Thrust, FABER, Distraction or Gaenslen's\n\n          -  Subject has documentation of failed, non-operative management of SIJ pain for \u2265 6\n             months prior to surgery; for example, use of medications, braces, SI belts,\n             orthotics, physical therapy or manual manipulation\n\n          -  The subject has two (2) positive diagnostic SIJ injections, fluoroscopically guided,\n             with two different local anesthetics. The first injection using a numbing agent (e.g.\n             lidocaine) and the second injection using a different numbing agent (e.g.\n             Bupivicaine) must both must result in a \u226575% decrease in pain from the anesthetic\n             portion of the injection\n\n          -  The subject has VAS back pain score of \u2265 60 mm\n\n          -  The subject has an ODI \u2265 40%\n\n          -  The subject is at least 18 years of age and skeletally mature\n\n          -  The subject agrees and is able to comply with study requirements\n\n        Exclusion Criteria:\n\n          -  Subjects contraindicated per the cleared labeling will be excluded from participation\n             in the study\n\n          -  The subject has pelvic soft tissue or bony tumors\n\n          -  The subject has had any trauma causing fracture of the sacrum or iliac bones or has\n             had spinal trauma leading to a neurological deficit\n\n          -  The subject has a history of a central nervous system (CNS) disorder(s)\n\n          -  The subject is pregnant or is planning on becoming pregnant in the next two years\n\n          -  The subject has chemical dependency problems as evidenced by a history of abusing\n             drugs which is documented in their past medical history or is elicited from an\n             interview\n\n          -  The subject has a history of significant emotional or psychosocial disturbance\n             (anxiety attacks, obsessive/compulsive disorders, depression or schizophrenia) as\n             documented in their past medical history or elicited by an interview"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients will be recruited from the Investigator's standard patient population diagnosed\n        with SIJ pain and representing candidates' for SIJ fusion."
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064322", 
            "org_study_id": "CLP 007-001"
        }, 
        "intervention": {
            "arm_group_label": "SImmetry Implant", 
            "description": "The SImmetry device consists of one 12.5mm SIJ Implant and one 6.5mm SIJ Implant. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.\nThe SImmetry Surgical Instruments consist of standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.", 
            "intervention_name": "SImmetry Implant", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "sacroiliac joint fusion", 
            "SIJ fusion", 
            "SI joint"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "emalick@spinecare.com", 
                "last_name": "Elizabeth Malick", 
                "phone": "650-985-7579"
            }, 
            "facility": {
                "address": {
                    "city": "Daly City", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94015"
                }, 
                "name": "SpineCare Medical Group"
            }, 
            "investigator": {
                "last_name": "Noel Goldthwaite, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "SAIF: Sacroiliac Fusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System", 
        "overall_contact": {
            "email": "lingham@zyga.com", 
            "last_name": "Lisa Ingham"
        }, 
        "overall_contact_backup": {
            "email": "clonghenry@zyga.com", 
            "last_name": "Caytie Longhenry"
        }, 
        "overall_official": {
            "affiliation": "SpineCare Medical Group", 
            "last_name": "Noel Goldthwaite, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Confirmed fusion of the SI joint at 12 and 24 months, defined as as presence of a continuous segment of solid bridging bone that extends from the sacrum to the ilium.", 
            "measure": "SI Joint Fusion", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064322"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "SI joint pain reduction evaluated by use of Visual Analogue Scale (VAS) for back pain for comparison of baseline to 12 and 24 months.", 
            "measure": "SI Joint Pain Reduction", 
            "safety_issue": "No", 
            "time_frame": "12 and 24 months"
        }, 
        "source": "Zyga Technology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zyga Technology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}